On Jan 09, major Wall Street analysts update their ratings for $Sana Biotechnology (SANA.US)$, with price targets ranging from $7 to $11.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $9.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and maintains the target price at $7.
TD Cowen analyst Marc Frahm upgrades to a buy rating.
H.C. Wainwright analyst Emily Bodnar maintains with a buy rating, and adjusts the target price from $8 to $11.
JMP Securities analyst Reni Benjamin maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Sana Biotechnology (SANA.US)$'s main analysts recently are as follows:
Political and rate uncertainty remains a concern, yet the health of the Biopharma sector is perceived as significantly better than its 2022 lows. Analysts continue to favor stories about late-stage clinical trials or early product launches. Additionally, Phase 1 clinical programs that offer derisking data and near-term catalysts are becoming increasingly important focal points for investors.
Positive data from Sana Biotechnology indicate that Hypoimmune modified cadaver islet cells sustained immune evasion and C-peptide production in a type 1 diabetes patient without immunosuppression. This data establishes a proof of concept for Hypoimmune's immune evasion properties and significantly derisks applications in type 1 diabetes and other fields. Although considerable work remains in terms of commercialization, the company is considered to have a notably changed risk profile.
Here are the latest investment ratings and price targets for $Sana Biotechnology (SANA.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間1月9日，多家華爾街大行更新了$Sana Biotechnology (SANA.US)$的評級，目標價介於7美元至11美元。
摩根士丹利分析師Vikram Purohit維持買入評級，維持目標價9美元。
美銀證券分析師Alec Stranahan維持買入評級，維持目標價7美元。
TD Cowen分析師Marc Frahm上調至買入評級。
H.C. Wainwright分析師Emily Bodnar維持買入評級，並將目標價從8美元上調至11美元。
JMP Securities分析師Reni Benjamin維持持有評級。
此外，綜合報道，$Sana Biotechnology (SANA.US)$近期主要分析師觀點如下：
政治和利率的不確定性仍然令人擔憂，但生物製藥板塊的健康狀況被認爲顯著好於2022年的低谷。分析師們繼續青睞關於晚期臨牀試驗或早期產品發佈的故事。此外，提供去風險數據和近期催化劑的第一階段臨牀項目正變得越來越重要，成爲投資者關注的焦點。
來自Sana生物技術的正面數據表明，低免疫修改後的屍體胰島細胞在一名未經免疫抑制的1型糖尿病患者中維持了免疫逃逸和C肽的產生。該數據爲低免疫的免疫逃逸屬性確立了概念證明，並顯著降低了在1型糖尿病和其他領域應用的風險。儘管在商業化方面仍需大量工作，但該公司的風險配置被認爲有顯著變化。
以下爲今日5位分析師對$Sana Biotechnology (SANA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
